Cullinan Therapeutics Inc. (CGEM) NASDAQ
$15.77 (2.30) (-12.71%)
Market Cap: $777.77M
As of 04/19/24 02:14 PM EDT. Market open.
Cullinan Therapeutics Inc. (CGEM)
NASDAQ
$15.77
(2.30) (-12.71%)
Market Cap: $777.77M
As of 04/19/24 02:14 PM EDT. Market open.
Add to Portfolio
cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating ... read more
cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model. read less
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO
Nadim Ahmed
Full Time Employees
73
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO
Nadim Ahmed
Full Time Employees
73
Address
One Main Street, Suite 1350, MA, Cambridge, 02142.
PRICE CHART FOR CULLINAN THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$18.02
Previous Close
$18.06
Days Range
$17.97 - $19.16
52 week range
$7.64 - $20.62
Volume
671,677
Avg. Volume (30 days)
527,401
Market Cap
$777.77M
Dividend Yield
-
P/E
-
Shares Outstanding
43,065,645
Open
$18.02
Previous Close
$18.06
Days Range
$17.97 - $19.16
52 week range
$7.64 - $20.62
Volume
671,677
Avg. Volume (30 days)
527,401
Market Cap
$777.77M
Dividend Yield
-
P/E
-
Shares Outstanding
43,065,645
FINANCIAL STATEMENTS FOR CULLINAN THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR CULLINAN THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Savill Corrine | Chief Business Officer | Feb 01, 2024 | Option Exercise | $4.30 | 40,000 | 172,000 | 205,990 | Feb 02, 2024, 09:35 PM |
| Savill Corrine | Chief Business Officer | Feb 01, 2024 | Sale | $16.18 | 40,000 | 647,200 | 165,990 | Feb 02, 2024, 09:35 PM |
| Savill Corrine | Chief Business Officer | Jan 29, 2024 | Option Exercise | $4.30 | 40,000 | 172,000 | 205,990 | Jan 30, 2024, 07:00 PM |
| Savill Corrine | Chief Business Officer | Jan 29, 2024 | Sale | $14.09 | 40,000 | 563,600 | 165,990 | Jan 30, 2024, 07:00 PM |
| Savill Corrine | Chief Business Officer | Jan 23, 2024 | Option Exercise | $4.30 | 21,316 | 91,659 | 187,306 | Jan 24, 2024, 05:00 PM |
| Savill Corrine | Chief Business Officer | Jan 22, 2024 | Option Exercise | $4.30 | 14,559 | 62,604 | 184,674 | Jan 24, 2024, 05:00 PM |
| Savill Corrine | Chief Business Officer | Jan 23, 2024 | Sale | $12.46 | 21,316 | 265,597 | 165,990 | Jan 24, 2024, 05:00 PM |
| Savill Corrine | Chief Business Officer | Jan 22, 2024 | Sale | $12.14 | 18,684 | 226,911 | 170,115 | Jan 24, 2024, 05:00 PM |
| AHMED NADIM | President and CEO | Dec 26, 2023 | Sale | $9.24 | 4,272 | 39,473 | 111,550 | Dec 27, 2023, 06:30 PM |
| Jones Jeffrey Alan | Chief Medical Officer | Dec 21, 2023 | Sale | $8.50 | 1,860 | 15,810 | 56,191 | Dec 22, 2023, 05:30 PM |
| SUMER JACQUELYN L | Chief Legal Officer | Dec 21, 2023 | Sale | $8.50 | 1,400 | 11,900 | 44,133 | Dec 22, 2023, 05:30 PM |
| Trigilio Jeffrey | Chief Financial Officer | Dec 21, 2023 | Sale | $8.50 | 1,920 | 16,320 | 83,919 | Dec 22, 2023, 05:30 PM |
| Michaelson Jennifer | Chief Scientific Officer | Dec 21, 2023 | Sale | $8.50 | 1,145 | 9,733 | 87,582 | Dec 22, 2023, 05:30 PM |
| Jones Jeffrey Alan | Chief Medical Officer | Dec 18, 2023 | Sale | $8.22 | 386 | 3,173 | 58,051 | Dec 20, 2023, 06:00 PM |
| Michaelson Jennifer | Chief Scientific Officer | Dec 18, 2023 | Sale | $8.22 | 238 | 1,956 | 88,727 | Dec 20, 2023, 06:00 PM |
| SUMER JACQUELYN L | Chief Legal Officer | Dec 18, 2023 | Sale | $8.22 | 290 | 2,384 | 45,533 | Dec 20, 2023, 06:00 PM |
| Trigilio Jeffrey | Chief Financial Officer | Dec 18, 2023 | Sale | $8.22 | 398 | 3,272 | 85,839 | Dec 20, 2023, 06:00 PM |
| Trigilio Jeffrey | Chief Financial Officer | Dec 12, 2023 | Sale | $7.81 | 1,926 | 15,042 | 86,237 | Dec 13, 2023, 08:00 PM |
| Michaelson Jennifer | Chief Scientific Officer | Dec 12, 2023 | Sale | $7.81 | 1,068 | 8,341 | 88,965 | Dec 13, 2023, 08:00 PM |
| Trigilio Jeffrey | Chief Financial Officer | Jun 30, 2023 | Option Exercise | $9.08 | 2,340 | 21,247 | 88,163 | Jul 05, 2023, 09:27 PM |
| AHMED NADIM | President and CEO | Jun 28, 2023 | Sale | $11.40 | 759 | 8,653 | 115,822 | Jun 29, 2023, 04:59 PM |
| Jones Jeffrey Alan | Chief Medical Officer | Jun 20, 2023 | Sale | $12.94 | 387 | 5,008 | 58,437 | Jun 21, 2023, 04:17 PM |
| Michaelson Jennifer | Chief Development Officer | Jun 20, 2023 | Sale | $12.94 | 238 | 3,080 | 90,033 | Jun 21, 2023, 04:17 PM |
| Trigilio Jeffrey | Chief Financial Officer | Jun 20, 2023 | Sale | $12.94 | 399 | 5,163 | 85,823 | Jun 21, 2023, 04:17 PM |
| SUMER JACQUELYN L | Chief Legal Officer | Jun 20, 2023 | Sale | $12.94 | 291 | 3,766 | 45,823 | Jun 21, 2023, 04:17 PM |
| Trigilio Jeffrey | Chief Financial Officer | Jun 12, 2023 | Sale | $13.11 | 319 | 4,182 | 86,222 | Jun 14, 2023, 04:35 PM |
| Michaelson Jennifer | Chief Development Officer | Jun 12, 2023 | Sale | $13.11 | 176 | 2,307 | 90,271 | Jun 14, 2023, 04:35 PM |
| Michaelson Jennifer | Chief Development Officer | Jun 07, 2023 | Option Exercise | $4.30 | 100 | 430 | 90,547 | Jun 08, 2023, 05:10 PM |
| Michaelson Jennifer | Chief Development Officer | Jun 06, 2023 | Option Exercise | $4.30 | 11,900 | 51,170 | 102,347 | Jun 08, 2023, 05:10 PM |
| Michaelson Jennifer | Chief Development Officer | Jun 06, 2023 | Sale | $12.31 | 11,900 | 146,489 | 90,447 | Jun 08, 2023, 05:10 PM |
| Michaelson Jennifer | Chief Development Officer | Jun 07, 2023 | Sale | $12.40 | 100 | 1,240 | 90,447 | Jun 08, 2023, 05:10 PM |
| AHMED NADIM | President and CEO | May 23, 2023 | Sale | $9.15 | 707 | 6,469 | 116,581 | May 24, 2023, 04:36 PM |
| Michaelson Jennifer | Chief Development Officer | May 18, 2023 | Sale | $8.76 | 239 | 2,094 | 90,447 | May 19, 2023, 04:51 PM |
| Jones Jeffrey Alan | Chief Medical Officer | May 18, 2023 | Sale | $8.76 | 394 | 3,451 | 58,824 | May 19, 2023, 04:46 PM |
| SUMER JACQUELYN L | Chief Legal Officer | May 18, 2023 | Sale | $8.76 | 291 | 2,549 | 46,114 | May 19, 2023, 04:45 PM |
| Trigilio Jeffrey | Chief Financial Officer | May 18, 2023 | Sale | $8.76 | 399 | 3,495 | 86,541 | May 19, 2023, 04:44 PM |
| Michaelson Jennifer | Chief Development Officer | May 12, 2023 | Sale | $8.78 | 193 | 1,695 | 90,686 | May 16, 2023, 05:36 PM |
| Trigilio Jeffrey | Chief Financial Officer | May 12, 2023 | Sale | $8.78 | 347 | 3,047 | 86,940 | May 16, 2023, 05:28 PM |
| AHMED NADIM | President and CEO | Apr 25, 2023 | Sale | $10.59 | 716 | 7,582 | 117,288 | Apr 26, 2023, 04:23 PM |
| Jones Jeffrey Alan | Chief Medical Officer | Apr 18, 2023 | Sale | $10.71 | 392 | 4,198 | 59,218 | Apr 20, 2023, 04:38 PM |
| Trigilio Jeffrey | Chief Financial Officer | Apr 18, 2023 | Sale | $10.71 | 398 | 4,263 | 87,287 | Apr 20, 2023, 04:34 PM |
| Michaelson Jennifer | Chief Development Officer | Apr 18, 2023 | Sale | $10.71 | 238 | 2,549 | 90,879 | Apr 20, 2023, 04:32 PM |
| SUMER JACQUELYN L | Chief Legal Officer | Apr 18, 2023 | Sale | $10.71 | 290 | 3,106 | 46,405 | Apr 20, 2023, 04:30 PM |
| Trigilio Jeffrey | Chief Financial Officer | Apr 12, 2023 | Sale | $10.22 | 318 | 3,250 | 87,685 | Apr 14, 2023, 06:35 PM |
| Michaelson Jennifer | Chief Development Officer | Apr 12, 2023 | Sale | $10.22 | 176 | 1,799 | 91,117 | Apr 14, 2023, 06:23 PM |
| Trigilio Jeffrey | Chief Financial Officer | Mar 20, 2023 | Sale | $11.32 | 399 | 4,517 | 88,003 | Mar 27, 2023, 04:05 PM |
| Jones Jeffrey Alan | Chief Medical Officer | Mar 20, 2023 | Sale | $11.32 | 390 | 4,415 | 59,610 | Mar 27, 2023, 04:05 PM |
| Michaelson Jennifer | Chief Development Officer | Mar 20, 2023 | Sale | $11.32 | 238 | 2,694 | 91,293 | Mar 27, 2023, 04:05 PM |
| SUMER JACQUELYN L | Chief Legal Officer | Mar 20, 2023 | Sale | $11.32 | 305 | 3,453 | 46,695 | Mar 27, 2023, 04:05 PM |
| AHMED NADIM | President and CEO | Mar 23, 2023 | Sale | $10.51 | 706 | 7,420 | 118,004 | Mar 27, 2023, 04:05 PM |
| Trigilio Jeffrey | Chief Financial Officer | Dec 30, 2022 | Option Exercise | $8.97 | 201 | 1,803 | 41,402 | Jan 06, 2023, 01:48 PM |
| Michaelson Jennifer | See Remarks | Nov 25, 2022 | Option Exercise | $4.30 | 4,000 | 17,200 | 57,031 | Nov 29, 2022, 04:05 PM |
| Michaelson Jennifer | See Remarks | Nov 25, 2022 | Sale | $13.30 | 4,000 | 53,200 | 53,031 | Nov 29, 2022, 04:05 PM |
| Michaelson Jennifer | See Remarks | Sep 27, 2022 | Option Exercise | $4.30 | 4,000 | 17,200 | 57,031 | Sep 29, 2022, 04:05 PM |
| Michaelson Jennifer | See Remarks | Sep 27, 2022 | Sale | $12.40 | 4,000 | 49,600 | 53,031 | Sep 29, 2022, 04:05 PM |
| Michaelson Jennifer | Chief Development Officer | Aug 08, 2022 | Option Exercise | $4.30 | 1,385 | 5,956 | 54,416 | Aug 09, 2022, 05:36 PM |
| Michaelson Jennifer | Chief Development Officer | Aug 08, 2022 | Sale | $15.01 | 1,385 | 20,789 | 53,031 | Aug 09, 2022, 05:36 PM |
| F2 Vision SCS | 10% Owner | Aug 04, 2022 | Sale | $14.31 | 25,989 | 371,788 | 1,255,963 | Aug 04, 2022, 09:01 PM |
| F2 Vision SCS | 10% Owner | Aug 03, 2022 | Sale | $14.24 | 19,129 | 272,334 | 1,281,952 | Aug 04, 2022, 09:01 PM |
| F2 Vision SCS | 10% Owner | Aug 02, 2022 | Sale | $14.10 | 4,792 | 67,554 | 1,301,081 | Aug 04, 2022, 09:01 PM |
| Michaelson Jennifer | Chief Development Officer | Jul 25, 2022 | Option Exercise | $4.30 | 8,000 | 34,400 | 61,031 | Jul 26, 2022, 05:44 PM |
| Michaelson Jennifer | Chief Development Officer | Jul 25, 2022 | Sale | $14.51 | 8,000 | 116,080 | 53,031 | Jul 26, 2022, 05:44 PM |
| Savill Corrine | Acting Chief Business Officer | Jul 19, 2022 | Sale | $15.22 | 14,958 | 227,661 | 149,615 | Jul 21, 2022, 04:30 PM |
| Savill Corrine | Acting Chief Business Officer | Jul 18, 2022 | Sale | $15.06 | 5,042 | 75,933 | 164,573 | Jul 21, 2022, 04:30 PM |
| Savill Corrine | Acting Chief Business Officer | Jul 11, 2022 | Sale | $13.33 | 40,000 | 533,304 | 169,815 | Jul 12, 2022, 04:14 PM |
| Michaelson Jennifer | Chief Development Officer | Jun 30, 2022 | Option Exercise | $10.90 | 1,620 | 17,658 | 53,031 | Jul 05, 2022, 06:10 PM |
| Trigilio Jeffrey | Chief Financial Officer | Jun 30, 2022 | Option Exercise | $10.90 | 1,451 | 15,816 | 41,201 | Jul 05, 2022, 06:08 PM |
| AHMED NADIM | President and CEO | Jun 30, 2022 | Option Exercise | $10.90 | 1,620 | 17,658 | 9,710 | Jul 05, 2022, 06:04 PM |
| Jovan-Embiricos Morana | 10% Owner | Jun 24, 2022 | Option Exercise | $13.39 | 45,078 | 603,594 | 207,803 | Jun 28, 2022, 09:24 PM |
| Jovan-Embiricos Morana | 10% Owner | Jun 24, 2022 | Option Exercise | $4.30 | 140,374 | 603,608 | 252,881 | Jun 28, 2022, 09:24 PM |
| F2 Bioscience I 2017 Ltd | 10% Owner | Jun 23, 2022 | Sale | $13.00 | 29,631 | 385,310 | 537,392 | Jun 23, 2022, 06:47 PM |
| F2 Bioscience I 2017 Ltd | 10% Owner | Jun 22, 2022 | Sale | $12.70 | 49,953 | 634,578 | 567,023 | Jun 23, 2022, 06:47 PM |
| F2 Bioscience I 2017 Ltd | 10% Owner | Jun 21, 2022 | Sale | $12.77 | 22,319 | 284,929 | 616,976 | Jun 23, 2022, 06:47 PM |
| AHMED NADIM | President and CEO | Jun 06, 2022 | Buy | $12.40 | 8,090 | 100,316 | 8,090 | Jun 07, 2022, 04:33 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 01, 2022 | Buy | $11.00 | 751,396 | 8,264,905 | 4,058,854 | Jun 03, 2022, 06:24 PM |
| F2 Vision SCS | 10% Owner | May 16, 2022 | Sale | $11.23 | 35,158 | 394,828 | 1,305,873 | May 16, 2022, 08:54 PM |
| F2 Vision SCS | 10% Owner | May 13, 2022 | Sale | $10.11 | 119,508 | 1,208,377 | 1,375,220 | May 16, 2022, 08:54 PM |
| F2 Vision SCS | 10% Owner | May 12, 2022 | Sale | $9.25 | 264,072 | 2,442,587 | 1,460,539 | May 16, 2022, 08:54 PM |
| BVF PARTNERS L P/IL | 10% Owner | May 13, 2022 | Buy | $9.14 | 109,900 | 1,003,937 | 3,653,213 | May 16, 2022, 07:34 PM |
| BVF PARTNERS L P/IL | 10% Owner | May 12, 2022 | Buy | $9.06 | 1,000,000 | 9,060,000 | 3,599,615 | May 16, 2022, 07:34 PM |
| BVF PARTNERS L P/IL | 10% Owner | Apr 01, 2022 | Buy | $10.75 | 276,000 | 2,966,972 | 3,056,616 | Apr 05, 2022, 06:45 PM |
| Michaelson Jennifer | See Remarks | Oct 18, 2021 | Option Exercise | $4.30 | 4,000 | 17,200 | 26,911 | Oct 20, 2021, 04:30 PM |
| Michaelson Jennifer | See Remarks | Oct 18, 2021 | Sale | $21.42 | 4,000 | 85,669 | 23,515 | Oct 20, 2021, 04:30 PM |
| Trigilio Jeffrey | Chief Financial Officer | Oct 15, 2021 | Option Exercise | $4.30 | 8,000 | 34,400 | 10,250 | Oct 18, 2021, 04:15 PM |
| Trigilio Jeffrey | Chief Financial Officer | Oct 15, 2021 | Sale | $25.00 | 8,000 | 200,000 | 2,250 | Oct 18, 2021, 04:15 PM |
| Zawel Leigh | See Remarks | Oct 15, 2021 | Sale | $25.00 | 19,574 | 489,350 | 37,285 | Oct 18, 2021, 04:15 PM |
| Zawel Leigh | See Remarks | Oct 07, 2021 | Sale | $25.00 | 1,079 | 26,975 | 56,859 | Oct 12, 2021, 04:30 PM |
| Michaelson Jennifer | See Remarks | Sep 20, 2021 | Option Exercise | $4.30 | 4,000 | 17,200 | 26,911 | Sep 21, 2021, 04:30 PM |
| Michaelson Jennifer | See Remarks | Sep 20, 2021 | Sale | $24.51 | 4,000 | 98,048 | 23,711 | Sep 21, 2021, 04:30 PM |
| Zawel Leigh | See Remarks | Sep 20, 2021 | Sale | $25.16 | 7,468 | 187,895 | 57,938 | Sep 21, 2021, 04:30 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 16, 2021 | Sale | $29.06 | 3,124 | 90,783 | 7,648,268 | Sep 20, 2021, 05:31 PM |
| GADICKE ANSBERT | Director | Sep 16, 2021 | Sale | $29.06 | 3,124 | 90,783 | 7,648,268 | Sep 20, 2021, 05:30 PM |
| GADICKE ANSBERT | Director | Sep 16, 2021 | Sale | $29.06 | 432 | 12,554 | 244,551 | Sep 20, 2021, 05:30 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 15, 2021 | Sale | $29.16 | 6,425 | 187,353 | 7,651,392 | Sep 16, 2021, 04:45 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 14, 2021 | Sale | $29.17 | 7,106 | 207,282 | 7,657,817 | Sep 16, 2021, 04:45 PM |
| GADICKE ANSBERT | Director | Sep 15, 2021 | Sale | $29.16 | 6,425 | 187,353 | 7,651,392 | Sep 16, 2021, 04:44 PM |
| GADICKE ANSBERT | Director | Sep 15, 2021 | Sale | $29.16 | 888 | 25,894 | 244,983 | Sep 16, 2021, 04:44 PM |
| GADICKE ANSBERT | Director | Sep 14, 2021 | Sale | $29.17 | 7,106 | 207,282 | 7,657,817 | Sep 16, 2021, 04:44 PM |
| GADICKE ANSBERT | Director | Sep 14, 2021 | Sale | $29.17 | 982 | 28,645 | 245,871 | Sep 16, 2021, 04:44 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 13, 2021 | Sale | $29.10 | 3,595 | 104,615 | 7,664,923 | Sep 13, 2021, 06:24 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 10, 2021 | Sale | $29.04 | 5,931 | 172,236 | 7,668,518 | Sep 13, 2021, 06:24 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 09, 2021 | Sale | $29.35 | 13,727 | 402,887 | 7,674,449 | Sep 13, 2021, 06:24 PM |
| GADICKE ANSBERT | Director | Sep 09, 2021 | Sale | $29.35 | 13,727 | 402,887 | 7,674,449 | Sep 13, 2021, 06:22 PM |
| GADICKE ANSBERT | Director | Sep 09, 2021 | Sale | $29.35 | 1,898 | 55,706 | 248,170 | Sep 13, 2021, 06:22 PM |
| GADICKE ANSBERT | Director | Sep 13, 2021 | Sale | $29.10 | 3,595 | 104,615 | 7,664,923 | Sep 13, 2021, 06:22 PM |
| GADICKE ANSBERT | Director | Sep 13, 2021 | Sale | $29.10 | 497 | 14,463 | 246,853 | Sep 13, 2021, 06:22 PM |
| GADICKE ANSBERT | Director | Sep 10, 2021 | Sale | $29.04 | 5,931 | 172,236 | 7,668,518 | Sep 13, 2021, 06:22 PM |
| GADICKE ANSBERT | Director | Sep 10, 2021 | Sale | $29.04 | 820 | 23,813 | 247,350 | Sep 13, 2021, 06:22 PM |
| Baeuerle Patrick | See Remarks | Sep 08, 2021 | Option Exercise | $4.30 | 11,000 | 47,300 | 11,000 | Sep 09, 2021, 04:15 PM |
| Baeuerle Patrick | See Remarks | Sep 08, 2021 | Sale | $28.45 | 11,000 | 312,950 | 0 | Sep 09, 2021, 04:15 PM |
| Trigilio Jeffrey | Chief Financial Officer | Sep 08, 2021 | Option Exercise | $4.30 | 15,000 | 64,500 | 17,250 | Sep 09, 2021, 04:15 PM |
| Trigilio Jeffrey | Chief Financial Officer | Sep 08, 2021 | Sale | $28.48 | 15,000 | 427,153 | 11,763 | Sep 09, 2021, 04:15 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 08, 2021 | Sale | $29.11 | 10,842 | 315,611 | 7,688,176 | Sep 08, 2021, 06:20 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 07, 2021 | Sale | $29.04 | 25,067 | 727,946 | 7,699,018 | Sep 08, 2021, 06:20 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 03, 2021 | Sale | $29.60 | 12,731 | 376,838 | 7,724,085 | Sep 08, 2021, 06:20 PM |
| GADICKE ANSBERT | Director | Sep 07, 2021 | Sale | $29.04 | 3,465 | 100,624 | 251,567 | Sep 08, 2021, 06:17 PM |
| GADICKE ANSBERT | Director | Sep 03, 2021 | Sale | $29.60 | 12,731 | 376,838 | 7,724,085 | Sep 08, 2021, 06:17 PM |
| GADICKE ANSBERT | Director | Sep 03, 2021 | Sale | $29.60 | 1,760 | 52,096 | 255,032 | Sep 08, 2021, 06:17 PM |
| GADICKE ANSBERT | Director | Sep 08, 2021 | Sale | $29.11 | 10,842 | 315,611 | 7,688,176 | Sep 08, 2021, 06:17 PM |
| GADICKE ANSBERT | Director | Sep 08, 2021 | Sale | $29.11 | 1,499 | 43,636 | 250,068 | Sep 08, 2021, 06:17 PM |
| GADICKE ANSBERT | Director | Sep 07, 2021 | Sale | $29.04 | 25,067 | 727,946 | 7,699,018 | Sep 08, 2021, 06:17 PM |
| Zawel Leigh | See Remarks | Sep 07, 2021 | Sale | $28.95 | 28,118 | 814,016 | 65,406 | Sep 08, 2021, 04:15 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 02, 2021 | Sale | $29.46 | 15,757 | 464,201 | 7,736,816 | Sep 02, 2021, 05:26 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Sep 01, 2021 | Sale | $29.47 | 5,714 | 168,392 | 7,752,573 | Sep 02, 2021, 05:26 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Aug 31, 2021 | Sale | $29.82 | 2,838 | 84,625 | 7,759,840 | Sep 02, 2021, 05:26 PM |
| GADICKE ANSBERT | Director | Sep 02, 2021 | Sale | $29.46 | 15,757 | 464,201 | 7,736,816 | Sep 02, 2021, 05:25 PM |
| GADICKE ANSBERT | Director | Sep 02, 2021 | Sale | $29.46 | 2,178 | 64,164 | 256,792 | Sep 02, 2021, 05:25 PM |
| GADICKE ANSBERT | Director | Sep 01, 2021 | Sale | $29.47 | 5,714 | 168,392 | 7,752,573 | Sep 02, 2021, 05:25 PM |
| GADICKE ANSBERT | Director | Sep 01, 2021 | Sale | $29.47 | 790 | 23,281 | 258,970 | Sep 02, 2021, 05:25 PM |
| GADICKE ANSBERT | Director | Aug 31, 2021 | Sale | $29.82 | 2,838 | 84,625 | 7,759,840 | Sep 02, 2021, 05:25 PM |
| GADICKE ANSBERT | Director | Aug 31, 2021 | Sale | $29.82 | 392 | 11,689 | 259,975 | Sep 02, 2021, 05:25 PM |
| GADICKE ANSBERT | Director | Aug 30, 2021 | Sale | $29.30 | 31,001 | 908,329 | 7,761,125 | Aug 31, 2021, 04:48 PM |
| GADICKE ANSBERT | Director | Aug 30, 2021 | Sale | $29.30 | 4,285 | 125,550 | 260,152 | Aug 31, 2021, 04:48 PM |
| GADICKE ANSBERT | Director | Aug 27, 2021 | Sale | $29.09 | 13,357 | 388,555 | 7,792,126 | Aug 31, 2021, 04:48 PM |
| GADICKE ANSBERT | Director | Aug 27, 2021 | Sale | $29.09 | 1,846 | 53,700 | 264,437 | Aug 31, 2021, 04:48 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Aug 30, 2021 | Sale | $29.30 | 31,001 | 908,329 | 7,761,125 | Aug 31, 2021, 04:47 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Aug 27, 2021 | Sale | $29.09 | 13,357 | 388,555 | 7,792,126 | Aug 31, 2021, 04:47 PM |
| Zawel Leigh | See Remarks | Aug 09, 2021 | Sale | $26.57 | 21,204 | 563,333 | 130,256 | Aug 26, 2021, 07:20 PM |
| Zawel Leigh | See Remarks | Aug 10, 2021 | Sale | $27.41 | 6,914 | 189,517 | 126,650 | Aug 26, 2021, 07:20 PM |
| Michaelson Jennifer | See Remarks | Aug 18, 2021 | Option Exercise | $4.30 | 4,000 | 17,200 | 26,911 | Aug 26, 2021, 07:15 PM |
| Michaelson Jennifer | See Remarks | Aug 18, 2021 | Sale | $27.66 | 4,000 | 110,648 | 24,048 | Aug 26, 2021, 07:15 PM |
| Zawel Leigh | See Remarks | Aug 23, 2021 | Sale | $29.00 | 28,118 | 815,422 | 93,524 | Aug 26, 2021, 07:14 PM |
| Baeuerle Patrick | See Remarks | Aug 10, 2021 | Option Exercise | $4.30 | 11,000 | 47,300 | 11,000 | Aug 26, 2021, 07:11 PM |
| Baeuerle Patrick | See Remarks | Aug 10, 2021 | Sale | $27.00 | 11,000 | 297,000 | 0 | Aug 26, 2021, 07:11 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Aug 25, 2021 | Sale | $29.09 | 1,713 | 49,831 | 7,805,483 | Aug 25, 2021, 07:42 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Aug 24, 2021 | Sale | $29.48 | 50,822 | 1,498,233 | 7,807,196 | Aug 25, 2021, 07:42 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Aug 23, 2021 | Sale | $29.11 | 53,359 | 1,553,281 | 7,858,018 | Aug 25, 2021, 07:42 PM |
| GADICKE ANSBERT | Director | Aug 24, 2021 | Sale | $29.48 | 7,025 | 207,097 | 266,520 | Aug 25, 2021, 07:41 PM |
| GADICKE ANSBERT | Director | Aug 23, 2021 | Sale | $29.11 | 53,359 | 1,553,281 | 7,858,018 | Aug 25, 2021, 07:41 PM |
| GADICKE ANSBERT | Director | Aug 23, 2021 | Sale | $29.11 | 7,376 | 214,715 | 273,545 | Aug 25, 2021, 07:41 PM |
| GADICKE ANSBERT | Director | Aug 25, 2021 | Sale | $29.09 | 1,713 | 49,831 | 7,805,483 | Aug 25, 2021, 07:41 PM |
| GADICKE ANSBERT | Director | Aug 25, 2021 | Sale | $29.09 | 237 | 6,894 | 266,283 | Aug 25, 2021, 07:41 PM |
| GADICKE ANSBERT | Director | Aug 24, 2021 | Sale | $29.48 | 50,882 | 1,500,001 | 7,807,196 | Aug 25, 2021, 07:41 PM |
| Zawel Leigh | See Remarks | Aug 23, 2021 | Sale | $29.00 | 28,118 | 815,422 | 93,524 | Aug 24, 2021, 04:06 PM |
| Michaelson Jennifer | See Remarks | Aug 18, 2021 | Option Exercise | $4.30 | 4,000 | 17,200 | 26,911 | Aug 24, 2021, 04:06 PM |
| Michaelson Jennifer | See Remarks | Aug 18, 2021 | Sale | $27.66 | 4,000 | 110,648 | 24,048 | Aug 24, 2021, 04:06 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Aug 11, 2021 | Sale | $29.05 | 2,510 | 72,915 | 7,911,377 | Aug 12, 2021, 04:55 PM |
| GADICKE ANSBERT | Director | Aug 11, 2021 | Sale | $29.05 | 2,510 | 72,915 | 7,911,377 | Aug 12, 2021, 04:54 PM |
| GADICKE ANSBERT | Director | Aug 11, 2021 | Sale | $29.05 | 347 | 10,080 | 280,921 | Aug 12, 2021, 04:54 PM |
| Zawel Leigh | See Remarks | Aug 10, 2021 | Sale | $27.41 | 6,914 | 189,517 | 126,650 | Aug 11, 2021, 04:15 PM |
| Zawel Leigh | See Remarks | Aug 09, 2021 | Sale | $26.57 | 21,204 | 563,333 | 130,256 | Aug 11, 2021, 04:15 PM |
| UBS Oncology Impact Fund L.P. | 10% Owner | Jan 12, 2021 | Buy | $21.00 | 300,000 | 6,300,000 | 7,913,887 | Jan 14, 2021, 05:54 PM |
| GADICKE ANSBERT | Director | Jan 12, 2021 | Buy | $21.00 | 300,000 | 6,300,000 | 7,913,887 | Jan 14, 2021, 05:51 PM |
| Jovan-Embiricos Morana | Director | Jan 12, 2021 | Buy | $21.00 | 200,000 | 4,200,000 | 622,175 | Jan 14, 2021, 05:30 PM |
| Hughes Owen | President and CEO | Jan 12, 2021 | Buy | $21.00 | 2,500 | 52,500 | 506,226 | Jan 14, 2021, 05:30 PM |
| Trigilio Jeffrey | Chief Financial Officer | Jan 12, 2021 | Buy | $21.00 | 2,250 | 47,250 | 2,250 | Jan 14, 2021, 05:30 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Savill Corrine | Chief Business Officer | 02/01/2024 | 172,000 |
| Savill Corrine | Chief Business Officer | 02/01/2024 | 647,200 |
| Savill Corrine | Chief Business Officer | 01/29/2024 | 172,000 |
| Savill Corrine | Chief Business Officer | 01/29/2024 | 563,600 |
| Savill Corrine | Chief Business Officer | 01/23/2024 | 91,659 |
| Savill Corrine | Chief Business Officer | 01/22/2024 | 62,604 |
| Savill Corrine | Chief Business Officer | 01/23/2024 | 265,597 |
| Savill Corrine | Chief Business Officer | 01/22/2024 | 226,911 |
| AHMED NADIM | President and CEO | 12/26/2023 | 39,473 |
| Jones Jeffrey Alan | Chief Medical Officer | 12/21/2023 | 15,810 |
| SUMER JACQUELYN L | Chief Legal Officer | 12/21/2023 | 11,900 |
| Trigilio Jeffrey | Chief Financial Officer | 12/21/2023 | 16,320 |
| Michaelson Jennifer | Chief Scientific Officer | 12/21/2023 | 9,733 |
| Jones Jeffrey Alan | Chief Medical Officer | 12/18/2023 | 3,173 |
| Michaelson Jennifer | Chief Scientific Officer | 12/18/2023 | 1,956 |
| SUMER JACQUELYN L | Chief Legal Officer | 12/18/2023 | 2,384 |
| Trigilio Jeffrey | Chief Financial Officer | 12/18/2023 | 3,272 |
| Trigilio Jeffrey | Chief Financial Officer | 12/12/2023 | 15,042 |
| Michaelson Jennifer | Chief Scientific Officer | 12/12/2023 | 8,341 |
| Trigilio Jeffrey | Chief Financial Officer | 06/30/2023 | 21,247 |
| AHMED NADIM | President and CEO | 06/28/2023 | 8,653 |
| Jones Jeffrey Alan | Chief Medical Officer | 06/20/2023 | 5,008 |
| Michaelson Jennifer | Chief Development Officer | 06/20/2023 | 3,080 |
| Trigilio Jeffrey | Chief Financial Officer | 06/20/2023 | 5,163 |
| SUMER JACQUELYN L | Chief Legal Officer | 06/20/2023 | 3,766 |
| Trigilio Jeffrey | Chief Financial Officer | 06/12/2023 | 4,182 |
| Michaelson Jennifer | Chief Development Officer | 06/12/2023 | 2,307 |
| Michaelson Jennifer | Chief Development Officer | 06/07/2023 | 430 |
| Michaelson Jennifer | Chief Development Officer | 06/06/2023 | 51,170 |
| Michaelson Jennifer | Chief Development Officer | 06/06/2023 | 146,489 |
| Michaelson Jennifer | Chief Development Officer | 06/07/2023 | 1,240 |
| AHMED NADIM | President and CEO | 05/23/2023 | 6,469 |
| Michaelson Jennifer | Chief Development Officer | 05/18/2023 | 2,094 |
| Jones Jeffrey Alan | Chief Medical Officer | 05/18/2023 | 3,451 |
| SUMER JACQUELYN L | Chief Legal Officer | 05/18/2023 | 2,549 |
| Trigilio Jeffrey | Chief Financial Officer | 05/18/2023 | 3,495 |
| Michaelson Jennifer | Chief Development Officer | 05/12/2023 | 1,695 |
| Trigilio Jeffrey | Chief Financial Officer | 05/12/2023 | 3,047 |
| AHMED NADIM | President and CEO | 04/25/2023 | 7,582 |
| Jones Jeffrey Alan | Chief Medical Officer | 04/18/2023 | 4,198 |
| Trigilio Jeffrey | Chief Financial Officer | 04/18/2023 | 4,263 |
| Michaelson Jennifer | Chief Development Officer | 04/18/2023 | 2,549 |
| SUMER JACQUELYN L | Chief Legal Officer | 04/18/2023 | 3,106 |
| Trigilio Jeffrey | Chief Financial Officer | 04/12/2023 | 3,250 |
| Michaelson Jennifer | Chief Development Officer | 04/12/2023 | 1,799 |
| Trigilio Jeffrey | Chief Financial Officer | 03/20/2023 | 4,517 |
| Jones Jeffrey Alan | Chief Medical Officer | 03/20/2023 | 4,415 |
| Michaelson Jennifer | Chief Development Officer | 03/20/2023 | 2,694 |
| SUMER JACQUELYN L | Chief Legal Officer | 03/20/2023 | 3,453 |
| AHMED NADIM | President and CEO | 03/23/2023 | 7,420 |
| Trigilio Jeffrey | Chief Financial Officer | 12/30/2022 | 1,803 |
| Michaelson Jennifer | See Remarks | 11/25/2022 | 17,200 |
| Michaelson Jennifer | See Remarks | 11/25/2022 | 53,200 |
| Michaelson Jennifer | See Remarks | 09/27/2022 | 17,200 |
| Michaelson Jennifer | See Remarks | 09/27/2022 | 49,600 |
| Michaelson Jennifer | Chief Development Officer | 08/08/2022 | 5,956 |
| Michaelson Jennifer | Chief Development Officer | 08/08/2022 | 20,789 |
| F2 Vision SCS | 10% Owner | 08/04/2022 | 371,788 |
| F2 Vision SCS | 10% Owner | 08/03/2022 | 272,334 |
| F2 Vision SCS | 10% Owner | 08/02/2022 | 67,554 |
| Michaelson Jennifer | Chief Development Officer | 07/25/2022 | 34,400 |
| Michaelson Jennifer | Chief Development Officer | 07/25/2022 | 116,080 |
| Savill Corrine | Acting Chief Business Officer | 07/19/2022 | 227,661 |
| Savill Corrine | Acting Chief Business Officer | 07/18/2022 | 75,933 |
| Savill Corrine | Acting Chief Business Officer | 07/11/2022 | 533,304 |
| Michaelson Jennifer | Chief Development Officer | 06/30/2022 | 17,658 |
| Trigilio Jeffrey | Chief Financial Officer | 06/30/2022 | 15,816 |
| AHMED NADIM | President and CEO | 06/30/2022 | 17,658 |
| Jovan-Embiricos Morana | 10% Owner | 06/24/2022 | 603,594 |
| Jovan-Embiricos Morana | 10% Owner | 06/24/2022 | 603,608 |
| F2 Bioscience I 2017 Ltd | 10% Owner | 06/23/2022 | 385,310 |
| F2 Bioscience I 2017 Ltd | 10% Owner | 06/22/2022 | 634,578 |
| F2 Bioscience I 2017 Ltd | 10% Owner | 06/21/2022 | 284,929 |
| AHMED NADIM | President and CEO | 06/06/2022 | 100,316 |
| BVF PARTNERS L P/IL | 10% Owner | 06/01/2022 | 8,264,905 |
| F2 Vision SCS | 10% Owner | 05/16/2022 | 394,828 |
| F2 Vision SCS | 10% Owner | 05/13/2022 | 1,208,377 |
| F2 Vision SCS | 10% Owner | 05/12/2022 | 2,442,587 |
| BVF PARTNERS L P/IL | 10% Owner | 05/13/2022 | 1,003,937 |
| BVF PARTNERS L P/IL | 10% Owner | 05/12/2022 | 9,060,000 |
| BVF PARTNERS L P/IL | 10% Owner | 04/01/2022 | 2,966,972 |
| Michaelson Jennifer | See Remarks | 10/18/2021 | 17,200 |
| Michaelson Jennifer | See Remarks | 10/18/2021 | 85,669 |
| Trigilio Jeffrey | Chief Financial Officer | 10/15/2021 | 34,400 |
| Trigilio Jeffrey | Chief Financial Officer | 10/15/2021 | 200,000 |
| Zawel Leigh | See Remarks | 10/15/2021 | 489,350 |
| Zawel Leigh | See Remarks | 10/07/2021 | 26,975 |
| Michaelson Jennifer | See Remarks | 09/20/2021 | 17,200 |
| Michaelson Jennifer | See Remarks | 09/20/2021 | 98,048 |
| Zawel Leigh | See Remarks | 09/20/2021 | 187,895 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/16/2021 | 90,783 |
| GADICKE ANSBERT | Director | 09/16/2021 | 90,783 |
| GADICKE ANSBERT | Director | 09/16/2021 | 12,554 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/15/2021 | 187,353 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/14/2021 | 207,282 |
| GADICKE ANSBERT | Director | 09/15/2021 | 187,353 |
| GADICKE ANSBERT | Director | 09/15/2021 | 25,894 |
| GADICKE ANSBERT | Director | 09/14/2021 | 207,282 |
| GADICKE ANSBERT | Director | 09/14/2021 | 28,645 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/13/2021 | 104,615 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/10/2021 | 172,236 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/09/2021 | 402,887 |
| GADICKE ANSBERT | Director | 09/09/2021 | 402,887 |
| GADICKE ANSBERT | Director | 09/09/2021 | 55,706 |
| GADICKE ANSBERT | Director | 09/13/2021 | 104,615 |
| GADICKE ANSBERT | Director | 09/13/2021 | 14,463 |
| GADICKE ANSBERT | Director | 09/10/2021 | 172,236 |
| GADICKE ANSBERT | Director | 09/10/2021 | 23,813 |
| Baeuerle Patrick | See Remarks | 09/08/2021 | 47,300 |
| Baeuerle Patrick | See Remarks | 09/08/2021 | 312,950 |
| Trigilio Jeffrey | Chief Financial Officer | 09/08/2021 | 64,500 |
| Trigilio Jeffrey | Chief Financial Officer | 09/08/2021 | 427,153 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/08/2021 | 315,611 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/07/2021 | 727,946 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/03/2021 | 376,838 |
| GADICKE ANSBERT | Director | 09/07/2021 | 100,624 |
| GADICKE ANSBERT | Director | 09/03/2021 | 376,838 |
| GADICKE ANSBERT | Director | 09/03/2021 | 52,096 |
| GADICKE ANSBERT | Director | 09/08/2021 | 315,611 |
| GADICKE ANSBERT | Director | 09/08/2021 | 43,636 |
| GADICKE ANSBERT | Director | 09/07/2021 | 727,946 |
| Zawel Leigh | See Remarks | 09/07/2021 | 814,016 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/02/2021 | 464,201 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 09/01/2021 | 168,392 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 08/31/2021 | 84,625 |
| GADICKE ANSBERT | Director | 09/02/2021 | 464,201 |
| GADICKE ANSBERT | Director | 09/02/2021 | 64,164 |
| GADICKE ANSBERT | Director | 09/01/2021 | 168,392 |
| GADICKE ANSBERT | Director | 09/01/2021 | 23,281 |
| GADICKE ANSBERT | Director | 08/31/2021 | 84,625 |
| GADICKE ANSBERT | Director | 08/31/2021 | 11,689 |
| GADICKE ANSBERT | Director | 08/30/2021 | 908,329 |
| GADICKE ANSBERT | Director | 08/30/2021 | 125,550 |
| GADICKE ANSBERT | Director | 08/27/2021 | 388,555 |
| GADICKE ANSBERT | Director | 08/27/2021 | 53,700 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 08/30/2021 | 908,329 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 08/27/2021 | 388,555 |
| Zawel Leigh | See Remarks | 08/09/2021 | 563,333 |
| Zawel Leigh | See Remarks | 08/10/2021 | 189,517 |
| Michaelson Jennifer | See Remarks | 08/18/2021 | 17,200 |
| Michaelson Jennifer | See Remarks | 08/18/2021 | 110,648 |
| Zawel Leigh | See Remarks | 08/23/2021 | 815,422 |
| Baeuerle Patrick | See Remarks | 08/10/2021 | 47,300 |
| Baeuerle Patrick | See Remarks | 08/10/2021 | 297,000 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 08/25/2021 | 49,831 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 08/24/2021 | 1,498,233 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 08/23/2021 | 1,553,281 |
| GADICKE ANSBERT | Director | 08/24/2021 | 207,097 |
| GADICKE ANSBERT | Director | 08/23/2021 | 1,553,281 |
| GADICKE ANSBERT | Director | 08/23/2021 | 214,715 |
| GADICKE ANSBERT | Director | 08/25/2021 | 49,831 |
| GADICKE ANSBERT | Director | 08/25/2021 | 6,894 |
| GADICKE ANSBERT | Director | 08/24/2021 | 1,500,001 |
| Zawel Leigh | See Remarks | 08/23/2021 | 815,422 |
| Michaelson Jennifer | See Remarks | 08/18/2021 | 17,200 |
| Michaelson Jennifer | See Remarks | 08/18/2021 | 110,648 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 08/11/2021 | 72,915 |
| GADICKE ANSBERT | Director | 08/11/2021 | 72,915 |
| GADICKE ANSBERT | Director | 08/11/2021 | 10,080 |
| Zawel Leigh | See Remarks | 08/10/2021 | 189,517 |
| Zawel Leigh | See Remarks | 08/09/2021 | 563,333 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 01/12/2021 | 6,300,000 |
| GADICKE ANSBERT | Director | 01/12/2021 | 6,300,000 |
| Jovan-Embiricos Morana | Director | 01/12/2021 | 4,200,000 |
| Hughes Owen | President and CEO | 01/12/2021 | 52,500 |
| Trigilio Jeffrey | Chief Financial Officer | 01/12/2021 | 47,250 |
Load More Insider Transactions
FUNDS WITH A POSITION IN CULLINAN THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 2,462,274 | 0.00064% | 10.11% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 655,664 | 0.0007% | 10.97% | Other |
| ORBIMED ADVISORS LLC | 544,848 | 0.11% | No change | Other |
| RENAISSANCE TECHNOLOGIES LLC | 264,088 | 0.00417% | 18.58% | Other |
| UBS OCONNOR LLC | 54,352 | 0.04% | -48.24% | Value |
| D. E. SHAW & CO., INC. | 48,919 | 0.00044% | 23.22% | Other |
CHANGE IN SHARES OUTSTANDING FOR CULLINAN THERAPEUTICS INC
STOCK BUYBACKS FOR CULLINAN THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.18%
1Q
06/30/2023
7.15%
2Q
03/31/2023
5.23%
3Q
12/31/2022
-8.56%
4Q
09/30/2022
-6.14%
5Q
06/30/2022
-7.70%
6Q
03/31/2022
-3.65%
7Q
12/31/2021
0.62%
8Q
09/30/2021
-1.45%
9Q
06/30/2021
-1.12%
10Q
03/31/2021
1.98%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR CULLINAN THERAPEUTICS INC
LOADING...